Last quarter (Q ), Syros Pharmaceuticals's total revenue was $6.28M, an increase of 21.58% from the same quarter last year. In Q, Syros Pharmaceuticals's net income was $-34.48M. See Syros Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	$ 25.24M	$ 23.49M	$ 15.09M	$ 1.98M	$ 2.05M	$ 1.10M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 138.00M	$ 122.91M	$ 97.39M	$ 79.72M	$ 66.35M	$ 55.79M
Operating Income	$ -112.76M	$ -99.42M	$ -82.30M	$ -77.74M	$ -64.30M	$ -54.69M
Net Non Operating Interest Income Expense	$ -3.72M	$ -3.82M	$ -1.37M	$ 2.30M	$ 2.02M	-
Other Income Expense	$ 7.01M	$ 16.68M	$ -375.00K	$ 2.30M	$ 2.02M	$ 676.00K
Pretax Income	$ -109.47M	$ -86.56M	$ -84.04M	$ -75.44M	$ -62.28M	$ -54.01M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -109.47M	$ -86.56M	$ -84.04M	$ -75.44M	$ -62.28M	$ -54.01M
Basic EPS	-	-	-	$ -1.88	$ -1.91	$ -2.13
Diluted EPS	-	-	-	$ -1.88	$ -1.91	$ -2.13
Basic Average Shares	-	-	-	$ 40.22M	$ 32.66M	$ 25.41M
Diluted Average Shares	-	-	-	$ 40.22M	$ 32.66M	$ 25.41M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 138.00M	$ 122.91M	$ 97.39M	$ 79.72M	$ 66.35M	$ 55.79M
Net Income From Continuing And Discontinued Operation	$ -109.47M	$ -86.56M	$ -84.04M	$ -75.44M	$ -62.28M	$ -54.01M
Normalized Income	$ -116.47M	$ -103.24M	$ -83.66M	$ -75.44M	$ -62.28M	$ -54.01M
Interest Expense	$ 3.93M	$ 3.91M	$ 1.79M	$ 72.00K	$ 1.00K	-
EBIT	$ -105.54M	$ -82.65M	$ -82.25M	$ -75.37M	$ -62.28M	$ -54.69M
EBITDA	$ -102.53M	$ -79.63M	$ -79.21M	$ -72.64M	$ -60.67M	$ -53.16M

Currency in USD

Syros Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing